CN1739707A - Dragon's blood extract with alpha-glycosidase inhibiting activity and its prepn making process and use - Google Patents
Dragon's blood extract with alpha-glycosidase inhibiting activity and its prepn making process and use Download PDFInfo
- Publication number
- CN1739707A CN1739707A CNA2005100282329A CN200510028232A CN1739707A CN 1739707 A CN1739707 A CN 1739707A CN A2005100282329 A CNA2005100282329 A CN A2005100282329A CN 200510028232 A CN200510028232 A CN 200510028232A CN 1739707 A CN1739707 A CN 1739707A
- Authority
- CN
- China
- Prior art keywords
- sanguis draxonis
- extract
- water
- alpha
- eluting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention belongs to the field of Chinese herbal medicine preparing technology, and the preparation process of dragon's blood extract includes the following steps: washing and pre-treatment of dragon's blood; supercritical extraction of dragon's blood at pressure of 10-30 MPa and CO2 flow rate of 25-35 kg/hr and collecting the residue as the coarse active extract; and refining to obtain dragon's blood extract with alpha-glycosidase inhibiting activity. The dragon's blood extract is further prepared into medicine capsule or tablet via adding supplementary material and water, and the medicine has powerful hypoglycemic effect.
Description
Technical field
The present invention relates to a kind of preparation technology's method and purposes, belong to Chinese herbal medicine fabricating technology field with Sanguis Draxonis extract and preparation thereof of alpha-glucoside inhibiting activity.
Background technology
Seek the active component that plays therapeutical effect in the Chinese medicine, confirm new drug target, study the mechanism of action of natural drug active substance, become the focus of Chinese medicine research.This seminar is a point of penetration with the Chinese medicine Sanguis Draxonis that diabetes is had definite curative effect, and research Sanguis Draxonis blood-sugar decreasing active and biological function are in conjunction with national conditions, performance traditional medicine and resources advantage, carry out an effective way of original new drug research.
Sanguis Draxonis (Dragon ' s Blood) be the precious Chinese medicine that is described as " panacea of invigorating blood circulation ", cure mainly the blood circulation promoting and blood stasis dispelling repercussive analgesic hemostatic and enrich blood.Modern study shows that Sanguis Draxonis has effects such as tangible antibiotic antioxidation, and this seminar finds that first Sanguis Draxonis extract also has very strong alpha-glucosidase and suppresses active function of blood sugar reduction on the basis of a large amount of experiments.
The material plant source of Sanguis Draxonis is not the single cropping thing, and main commodity Sanguis Draxonis is the kylin Sanguis Draxonis (Daemonorops draco B1.) of Palmae Daemonorops plant product and the Sanguis Draxonis (Dracaena) of Liliaceae dracaena plant product.Sanguis Draxonis always relies on import, is one of medical material in short supply, and the import Sanguis Draxonis is a Palmae kylin Sanguis Draxonis, costs an arm and a leg.What the Dracaena cochinchinensis (Dracaena cochinchinensis (Lour.) .S.C.Chen) that ground reserves such as Yunnan Province of China, Guangxi, Hainan are abundant produced is Sanguis Draxonis.Abundant natural resources and artificial introducing and planting have reduced cost, for condition has been created in the further investigation and the exploitation of natural drug Sanguis Draxonis that China's characteristic is arranged.
Diabetes can be divided into I type (insulin-dependent) and II type (non-insulin-depending type), and wherein II type patient accounts for nearly 90%.For the treatment of type ii diabetes, except insulin promotes secretogogue, euglycemic agent etc.,, alpha-glucosidase inhibitor has the active drug that reduces the post-prandial glycemia adjusting and improve abnormal carbohydrate metabolism thereby being a class.Alpha-glucosidase inhibitor is mainly by suppressing the alpha-glucosidase of small bowel cell brush border, delay the degraded of polysaccharide, disaccharidase or oligosaccharide in the intestinal, make the degradation of glucose of self-carbon water compound and be absorbed into blood speed and slow down, reduce the rising of post-prandial glycemia, stabilize blood glucose curve, the average blood sugar value is descended, and then play hypoglycemic effect.This seminar is in recent years from Sanguis Draxonis biological function mechanism, study the inhibitory action and the blood sugar lowering mechanism of its alpha-glucosidase, to suppress the alpha-glucosidase bioactive functions is guidance, extraction separation has obtained the effective site that blood sugar lowering inhibition vigor is higher than the full powder of Sanguis Draxonis targetedly from the full powder of Sanguis Draxonis, has set up the Sanguis Draxonis extract with alpha-glucoside inhibiting activity and the process of preparation thereof.
Summary of the invention
The object of the invention is to provide a kind of hypoglycemic process with Sanguis Draxonis extract and preparation thereof of alpha-glucoside inhibiting activity that is used for.
The present invention is a kind of process with Sanguis Draxonis extract and preparation thereof of alpha-glucoside inhibiting activity, it is characterized in that having following process and step:
A. the pretreatment of Sanguis Draxonis: remove a small amount of tannin and water miscible inorganic salt that exists in the Sanguis Draxonis with homemade automatic control liquid feeding eluting device eluting; This device is made up of high-order warm water's storage bottle, insulation interlayer eluting post, liquid receptacle three parts: the medicine material Sanguis Draxonis is pulverized, sieved, the warm distilled water or the deionized water that add 50 ℃-60 ℃, after the moistening that stirs fully absorbs water, gradation is packed in the insulation interlayer eluting post of eluting device, the dress post finishes, coated with filter paper and purification sea sand; The water that will be arranged in high-order warm water's storage bottle on its top is 50-60 ℃ by the temperature regulating device control water temperature, opens eluting post lower part outlet then, makes flow through eluting post and flow into from its underpart outlet and to connect filter of warm water in high-order warm water's storage bottle on top; Whole elution process is carried out under 50-60 ℃ of condition, and the amount of eluant is about 4-6 times of Sanguis Draxonis amount; Then with the Sanguis Draxonis behind the eluting in 60-80 ℃ of drying under reduced pressure, treat next step supercritical extraction;
B. the supercritical extraction of Sanguis Draxonis after the pretreatment: above-mentioned Sanguis Draxonis is ground, sieves, in the extraction kettle of the supercritical extraction unit of subsequently it being packed into, use supercritical CO
2Be solvent, carry out the supercritical extraction of Sanguis Draxonis, extracting pressure is 10-30Mpa, and temperature is 40-50 ℃, and the extraction time is 1-5 hour, CO
2Flow is 25-35kg/h; The resolving of extraction effluent is two-stage, the first order is resolved pressure 7-11Mpa, resolution temperature is 50-60 ℃, pressure 4-10Mpa is resolved in the second level, resolution temperature is 40-50 ℃, discards the extraction part, and the extracted residues in the extraction kettle is the Sanguis Draxonis effective site of removing the partial invalidity component, collect the crude extract of extracted residues as active component, to make with extra care Sanguis Draxonis blood sugar lowering extract with alpha-glucoside inhibiting activity:
C. refining Sanguis Draxonis blood sugar lowering extract: the circulation reflux device of the imitative Soxhlet extractor of an amplification of self-control with alpha-glucoside inhibiting activity, with the crude extract of the above-mentioned active component filtration paper cylinder of packing into, put into the infuser of homemade circulation reflux device, add acetone one ethyl acetate mixture that 5-8 doubly measures then, the proportioning of two kinds of solvents is 80%: 20% to 95%: 5%; Water bath heating temperature is 70-80 ℃, and extracting 4-8 hour repeatedly, after the extracting fully, leachate reclaimed solvent and is concentrated into dried; With extract obtained place vacuum desiccator 50-70 ℃ drying under reduced pressure 2-3 hour, take out extract, pulverize, sieve and obtain fine powder, this fine powder finished product is the Sanguis Draxonis blood sugar lowering extract based on the alpha-glucoside inhibiting activity of flavonoid;
D. the preparation of the refining extract formulation of Sanguis Draxonis: above-mentioned refining extract and pharmaceutical necessities are mixed with preparation, both ratios 4: 1-10: 1; Adjuvant can have been selected for use pharmaceutical necessities bonding, moistening, disintegration is as a kind of in starch, hydroxypropyl starch, microcrystalline Cellulose, dextrin, glycerol, ethyl cellulose, sodium carboxymethyl cellulose, sodium alginate, the agar or several; The weight of used water is 5-8 times of pharmaceutical necessities; Said extracted thing and pharmaceutical necessities are undertaken by the formulation weight ratio, earlier in pharmaceutical necessities, add an amount of water in proportion and be made into slurry, add Sanguis Draxonis extract subsequently while stirring, behind the mix homogeneously, make soft material, granulate, in 60-80 ℃ of drying under reduced pressure, grind, sieve, get fine powder, fine powder incapsulates or suppresses and promptly gets Dragonis sanguis preparation in flakes the most at last.
Prepared Sanguis Draxonis extract of the inventive method and preparation thereof, its purposes can be used as hypoglycemic drug.
The inventive method from Sanguis Draxonis targetedly extraction separation obtained having the extract of alpha-glucoside inhibiting activity, this extract suppresses inhibitor compound for the alpha-glucosidase based on flavonoid, it can make the glucose degradation of self-carbon water compound and the speed that is absorbed into blood to slow down, reduce the rising of post-prandial glycemia, the average blood sugar value is descended, and then play hypoglycemic effect.The present invention has created condition for the development and utilization of China's Chinese herbal medicine Sanguis Draxonis.
The specific embodiment:
After now specific embodiments of the invention further being described in.
Embodiment 1
The concrete step of preparation process of present embodiment Sanguis Draxonis extract and preparation thereof is as follows:
(1) Sanguis Draxonis pretreatment:
With warm water is solvent, removes a small amount of tannin and water miscible inorganic salt that exists in the Sanguis Draxonis with homemade automatic control liquid feeding eluting device eluting.This eluting device is made up of high-order warm water's storage bottle, insulation interlayer eluting post, liquid receptacle three parts, and assembling is fixed on the brandreth after connecting.Storage bottle is inverted, as to have a rubber closure 2500ml flask, is with the heater of band temperature control outward.The storage bottle below connects an insulation jacket eluting post, insulation jacket eluting column internal diameter Φ 10cm, length 50cm.Tool rubber closure suitable for reading, the end opening reducing is Φ 2cm, and is connected with glass piston.Liquid receptacle is the reagent bottle of a 3000ml.During eluting, the reagent bottleneck is aimed at the outlet of eluting post lower end and is got final product.
High-order storage bottle links to each other with two Φ 1.0cm glass tubings that are inserted in the rubber closure with the eluting post of below, and a glass-tube upper and lower side inserts respectively in the water of storage bottle and eluting post, and another glass-tube upper and lower side is inserted in the water layer top of storage bottle and eluting post respectively.On the rubber closure of eluting post, also be inserted with the glass-tube of a logical atmosphere Φ 1.0cm.
Before the eluting, Sanguis Draxonis is pulverized sieve No. four, took by weighing 300g, in beaker, added 55 ℃ warm deionized water.Add water 150ml, stir, evenly moistening after, it is fully absorbed water, take out after placing 30min, the gradation eluting post of packing into, the back of at every turn packing into evenly flattens with wooden unit, the dress post finishes, sea sand one deck of cleaning coated with filter paper and pretreatment.The eluting post is connected with storage bottle, and the temperature regulating device control water temperature of storage bottle heater is 55 ℃, and whole elution process is carried out under 55 ℃ of conditions.
Open eluting post lower part outlet piston, top storage bottle warm water then flows into the eluting post automatically, treats that the pillar air drains, and closes the lower part outlet piston, leaves standstill 1 hour, opens the outlet piston, regulates flow velocity, is generally 8ml/min.Eluent flows into receiving flask by lower part outlet.The amount of eluant is about 4 times of Sanguis Draxonis amount.Eluent filters with micropore (0.45 μ m) filter membrane, and incorporate in the Sanguis Draxonis that eluting finishes on film top, in 70 ℃ of drying under reduced pressure, dry thing 290g.Merge 10 batches, mixing is treated supercritical extraction.
(2) supercritical extraction of Sanguis Draxonis:
Sanguis Draxonis is worn into the middle powder that sieves for No. four, took by weighing 2.5kg, in the extraction kettle with its supercritical extraction unit of packing into, used supercritical CO
2Be solvent, carry out the supercritical extraction of Sanguis Draxonis, extracting pressure is 20Mpa, and temperature is 45 ℃, and the extraction time is 2 hours, CO
2Flow is 30kg/h; The resolving of supercritical extraction effluent is two-stage, the first order is resolved pressure 7Mpa, resolution temperature is 60 ℃, pressure 6.4Mpa is resolved in the second level, resolution temperature is 40 ℃, discard the extraction part, the extracted residues in the extraction kettle is the Sanguis Draxonis effective site of removing the partial invalidity component, collects the crude extract of extracted residues 2.36kg as active component.
(3) the Sanguis Draxonis crude extract is refining:
The circulation reflux device of the imitative Soxhlet extractor of an amplification of self-control, with the crude extract 300g of the active component filtration paper cylinder of packing into, then filtration paper cylinder is put into the infuser of reflux, add acetone-ethyl acetate (90: 10) mixed solution of 6 times of amounts, the water-bath temperature is 80 ℃, extracting 8 hours.After the extracting fully, extract reclaims solvent and is concentrated into dried.This extract placed 60 ℃ of drying under reduced pressure of vacuum drying apparatus 2 hours, took out, and was crushed to sieve No. six, and this fine powder is the Sanguis Draxonis blood sugar lowering extract with alpha-glucoside inhibiting activity based on flavone compound, and extract is 282g.
(4) preparation of Sanguis Draxonis extract preparation:
A. the capsule prescription with Sanguis Draxonis extract of alpha-glucoside inhibiting activity of the present invention is made up of Sanguis Draxonis extract and pharmaceutical necessities starch, and ratio is 9: 1.Preparation method is as follows: take by weighing Sanguis Draxonis extract 333g respectively in proportion, starch 37g, in the water boil impouring starch with 200ml, be made into starch slurry, add Sanguis Draxonis extract then while stirring, make soft material behind the mixing, granulate,, be milled to the fine powder of No. six sieves in 70 ℃ of drying under reduced pressure, adorn capsule No. 0, the tolerant loading amount of every intragranular is 0.37g.
B. the tablet formulation with Sanguis Draxonis extract of alpha-glucoside inhibiting activity of the present invention is made up of Sanguis Draxonis extract and pharmaceutical necessities hydroxypropyl starch, and ratio is 10: 1, makes tablet.Preparation method is as follows: take by weighing Sanguis Draxonis extract 370g respectively in proportion, hydroxypropyl starch 37g, in the water boil impouring hydroxypropyl starch with 200ml, be made into pulpous state, add Sanguis Draxonis extract then while stirring, make soft material behind the mixing, granulate, in 70 ℃ of drying under reduced pressure, granulate, with the tablet machine compacting in flakes, every weight is 0.40g.
Every performance test and effect thereof that the inventive method prepares resulting Sanguis Draxonis extract are as follows:
(1) Sanguis Draxonis extract is to the test of normal mouse fasting glucose influence
Kunming mouse, body weight 20 ± 2g, male, be divided into 5 groups at random, i.e. negative control group, positive controls, extract low dose group, middle dosage group and high dose group.Negative control group is irritated the stomach normal saline, and positive controls is irritated stomach glucobay (acarbose) 20mg/kg, and the Sanguis Draxonis extract low dose group is irritated stomach 100mg/kg, and middle dosage group is irritated stomach 300mg/kg, and high dose group is irritated stomach 500mg/kg.Successive administration 7 days, fasting 10h after the last administration, the eye socket venous sinus is got blood, (1% anticoagulant heparin), separation of serum, press the determination of glucose oxidase fasting glucose, gained is the result show: Sanguis Draxonis extract low dose group, middle dosage group and high dose group and negative control group contrast there was no significant difference.By table 1 as seen, successive administration is after 7 days, and each dosage treated animal fasting blood glucose level of Sanguis Draxonis extract has reduction slightly, but does not relatively have significant difference with matched group.This shows that each dosage group of Sanguis Draxonis extract do not have obvious influence to normal mouse blood sugar, and helping exploitation becomes the blood-sugar lowering tcm drug preparation.
Table 1 Sanguis Draxonis extract is to the test of normal mouse fasting glucose influence
| Group | Dosage (mg/kg) | Quantity (only) | Blood glucose value (mmol/L) |
| Negative control group | - | 10 | 4.01± 0.59 |
| The acarbose matched group | 20 | 10 | 3.79±0.71 |
| The Sanguis Draxonis extract low dose group | 100 | 10 | 3.97±0.49 |
| Dosage group in the Sanguis Draxonis extract | 300 | 10 | 3.86±0.80 |
| The Sanguis Draxonis extract high dose group | 500 | 10 | 3.74±0.78 |
(2) Sanguis Draxonis extract is to the influence of normal mouse carbohydrate tolerance
Kunming mouse, body weight 20 ± 2g, male.Be divided into 5 groups at random, i.e. negative control group, positive controls, extract low dose group, middle dosage group and high dose group.Negative control group is irritated the stomach normal saline, and positive controls is irritated stomach glucobay (acarbose) 20mg/kg, and the Sanguis Draxonis extract low dose group is irritated stomach 100mg/kg, and middle dosage group is irritated stomach 300mg/kg, and high dose group is irritated stomach 500mg/kg.Successive administration 7 days, fasting 8h before the last administration, sucrose after the administration (2.5g/kg) is irritated stomach, measures and gives after the sucrose 0.5,1, the blood glucose value of 2h, the blood sampling of eye socket venous sinus.Determination method of blood sugar is the same, and the gained data are organized a t check.The results are shown in Table 2.
Table 2 Sanguis Draxonis extract is to the influence of normal mouse carbohydrate tolerance
| Group | Dosage (mg/kg) | Quantity (only) | Blood glucose value (mmol/L) | |||
| 0h | 0.5h | 1h | 2h | |||
| Negative control group | - | 12 | 3.55± 1.08 | 7.25± 1.02 | 7.62± 1.21 | 7.24± 1.14 |
| The Acarbose matched group | 20 | 12 | 3.69± 0.96 | 5.33± 1.62* | 5.70± 1.57* | 5.87± 1.11* |
| The Sanguis Draxonis extract low dose group | 100 | 12 | 3.82± 1.64 | 6.38± 1.98 | 7.42± 2.41 | 6.78± 1.70 |
| Dosage group in the Sanguis Draxonis extract | 300 | 12 | 4.02± 1.63 | 5.76± 1.28* | 6.31± 1.20** | 6.01± 1.36** |
| The Sanguis Draxonis extract high dose group | 500 | 12 | 3.86± 1.73 | 4.25± 1.42* | 5.06± 2.32* | 4.89± 1.31* |
* P＜0.01, * * P＜0.05v.s. negative control group
As shown in Table 2, a little more than glucobay (acarbose), middle dosage group carbohydrate tolerance approaches glucobay (acarbose) to the Sanguis Draxonis extract low dose group to the carbohydrate tolerance data of normal mouse, and high dose is better than glucobay (acarbose) to the carbohydrate tolerance test of normal mouse.Illustrate that Sanguis Draxonis extract can delay the normal mouse post-prandial glycemia and raise, stabilize the blood sugar increasing curve.
(3) Sanguis Draxonis extract is to the inductive diabetic mice carbohydrate tolerance test of alloxan
80 of Kunming mouses, body weight 25 ± 2g, male.Behind the fasting 14h, lumbar injection 2% alloxan (200mg/kg) normal saline solution, fasting glucose (getting the preceding fasting 10h of blood) is measured in the blood sampling of injection 72h posterior orbit venous sinus, and determination method of blood sugar is the same.What blood glucose was higher than 11.1mmol/L is the diabetes model Mus.Model mouse is divided into 5 groups at random, 10 every group, is respectively model control group, positive controls, extract low dose group, middle dosage group and high dose group.Model control group is irritated the stomach normal saline, and positive controls is irritated stomach glucobay (acarbose) 20mg/kg, and the Sanguis Draxonis extract low dose group is irritated stomach 100mg/kg, and middle dosage group is irritated stomach 300mg/kg, and high dose group is irritated stomach 500mg/kg.Successive administration 10 days, fasting 8h before the last administration, sucrose after the administration (2.5g/kg) is irritated stomach, measures and gives after the sucrose 0.5,1, the blood glucose value of 2h, the blood sampling of eye socket venous sinus.Determination method of blood sugar is the same, and the gained data are organized a t check.The results are shown in Table 3.
As shown in Table 3, the middle and high dosage group of Sanguis Draxonis extract is better than glucobay (acarbose) to the carbohydrate tolerance test of the inductive diabetic mice of alloxan.Illustrate that Sanguis Draxonis extract can delay the inductive diabetic mice post-prandial glycemia of alloxan and raise, stabilize the blood sugar increasing curve.
Table 3 Sanguis Draxonis extract is to the carbohydrate tolerance test of the inductive diabetic mice of alloxan
| Group | Dosage (mg/kg) | Quantity (only) | Blood glucose value (mmol/L) | |||
| 0h | 0.5h | 1h | 2h | |||
| Model control group | 10 | 25.37± 1.19 | 36.54± 2.83 | 41.01± 4.84 | 36.11± 2.13 | |
| The Acarbose matched group | 20 | 10 | 25.72± 1.51 | 30.10± 4.39* | 30.54± 4.65* | 26.73± 3.34* |
| The Sanguis Draxonis extract low dose group | 100 | 10 | 25.87± 2.03 | 35.48± 3.45 | 38.14± 4.33 | 29.82± 4.51* |
| Dosage group in the Sanguis Draxonis extract | 300 | 9 | 25.98± 1.50 | 33.09± 3.95** | 34.71± 3.87* | 26.40± 2.60* |
| The Sanguis Draxonis extract high dose group | 500 | 9 | 26.28± 1.27 | 31.72± 2.60* | 32.21± 5.08* | 24.49± 4.22* |
* P＜0.01, * * P＜0.05v.s. model control group
(4) Sanguis Draxonis extract is to the blood glucose value test of the inductive diabetic mice of alloxan
The inductive diabetic mice of Kunming mouse alloxan is chosen blood glucose value and is experimentized the above person of 11.1mmol/L.Mice is divided into 5 groups, i.e. negative control group, positive controls, Sanguis Draxonis extract low dose group, middle dosage group and high dose group.Negative control group is irritated the stomach normal saline, and positive controls is irritated stomach glucobay (acarbose) 20mg/kg, and the extract low dose group is irritated stomach 100mg/kg, and middle dosage group is irritated stomach 300mg/kg, and high dose group is irritated stomach 500mg/kg.Successive administration 10 days, fasting 10h after the last administration, the eye socket venous sinus is got blood, and centrifuging and taking serum is pressed the determination of glucose oxidase blood sugar level, the results are shown in Table 4.
Table 4 Sanguis Draxonis extract is to the influence of the inductive blood glucose in diabetic mice value of alloxan
| Group | Dosage (mg/kg) | Quantity (only) | Blood glucose value (mmol/L) |
| Model control group | - | 10 | 22.74± 2.87 |
| The Acarbose matched group | 20 | 10 | 13.16±1.95 ** |
| The Sanguis Draxonis extract low dose group | 100 | 10 | 19.89±2.01 * |
| Dosage group in the Sanguis Draxonis extract | 300 | 9 | 14.38±2.13 ** |
| The Sanguis Draxonis extract high dose group | 500 | 9 | 13.32±1.79 ** |
* P＜0.05, * * P＜0.01v.s. model group,
As shown in Table 4, compare with diabetic model group, the basic, normal, high dosage group of Sanguis Draxonis extract can both significantly reduce the blood glucose (P＜0.01) of alloxan diabetes model mice, and middle and high dosage group and the similar hypoglycemic effect of positive controls acarbose tool.Diabetic model group adopts alloxan optionally to destroy beta Cell of islet in the experiment, thereby causes mouse blood sugar to raise.This shows that Sanguis Draxonis extract has and weakens alloxan to the damage of beta Cell of islet or improve the function of damaged cell, thus the symptom of diabetes-alleviating mice.
Claims (2)
1. preparation technology's method with Chinese medicine Sanguis Draxonis extract and preparation thereof of alpha-glucoside inhibiting activity.
It is characterized in that having following technical process and step:
A. the pretreatment of Sanguis Draxonis: remove a small amount of tannin and water miscible inorganic salt that exists in the Sanguis Draxonis with homemade automatic control liquid feeding eluting device eluting; This device is made up of high-order warm water's storage bottle, insulation interlayer eluting post, liquid receptacle three parts; The medicine material Sanguis Draxonis is pulverized, sieved, adds 50 ℃-60 ℃ warm distilled water or deionized water, after the moistening that stirs fully absorbed water, gradation was packed in the insulation interlayer eluting post of eluting device, and the dress post finishes, coated with filter paper and purification sea sand; The water that will be arranged in high-order warm water's storage bottle on its top is 50-60 ℃ by the temperature regulating device control water temperature, opens eluting post lower part outlet then, makes flow through eluting post and flow into liquid receptacle from its underpart outlet of warm water in high-order warm water's storage bottle on top; Whole elution process is carried out under 50-60 ℃ of condition, and the amount of eluant is about 4-6 times of Sanguis Draxonis amount; Then with the Sanguis Draxonis behind the eluting in 60-80 ℃ of drying under reduced pressure, treat next step supercritical extraction;
B. the supercritical extraction of Sanguis Draxonis after the pretreatment: above-mentioned Sanguis Draxonis is ground, sieves, in the extraction kettle of the supercritical extraction unit of subsequently it being packed into, use supercritical CO
2Be solvent, carry out the supercritical extraction of Sanguis Draxonis, extracting pressure is 10-30Mpa, and temperature is 40-50 ℃, and the extraction time is 1-5 hour, CO
2Flow is 25-35kg/h; The resolving of extraction effluent is two-stage, the first order is resolved pressure 7-11Mpa, resolution temperature is 50-60 ℃, pressure 4-10Mpa is resolved in the second level, resolution temperature is 40-50 ℃, discards the extraction part, and the extracted residues in the extraction kettle is the Sanguis Draxonis effective site of removing the partial invalidity component, collect the crude extract of extracted residues, with refining Sanguis Draxonis blood sugar lowering extract with alpha-glucoside inhibiting activity as active component;
C. refining Sanguis Draxonis blood sugar lowering extract: the circulation reflux device of the imitative Soxhlet extractor of an amplification of self-control with alpha-glucoside inhibiting activity, with the crude extract of the above-mentioned active component filtration paper cylinder of packing into, put into the infuser of homemade circulation reflux device, add acetone-ethyl acetate mixture that 5-8 doubly measures then, the proportioning of two kinds of solvents is 80%: 20% to 95%: 5%; Water bath heating temperature is 70-80 ℃, and extracting 4-8 hour repeatedly, after the extracting fully, leachate reclaimed solvent and is concentrated into dried; With extract obtained place vacuum desiccator 50-70 ℃ drying under reduced pressure 2-3 hour, take out extract, pulverize, sieve and obtain fine powder, this fine powder finished product is the Sanguis Draxonis blood sugar lowering extract based on the alpha-glucoside inhibiting activity of flavonoid;
D. the preparation of the refining extract formulation of Sanguis Draxonis: above-mentioned refining extract and pharmaceutical necessities are mixed with preparation, both ratios 4: 1-10: 1; Adjuvant can have been selected for use pharmaceutical necessities bonding, moistening, disintegration is as a kind of in starch, hydroxypropyl starch, microcrystalline Cellulose, dextrin, glycerol, ethyl cellulose, sodium carboxymethyl cellulose, sodium alginate, the agar or several; The weight of used water is 4-6 times of pharmaceutical necessities; Said extracted thing and pharmaceutical necessities are undertaken by the formulation weight ratio, earlier in pharmaceutical necessities, add an amount of water in proportion and be made into slurry, add Sanguis Draxonis extract subsequently while stirring, behind the mix homogeneously, make soft material, granulate, in 60-80 ℃ of drying under reduced pressure, grind, sieve, get fine powder, fine powder incapsulates or suppresses and promptly gets Dragonis sanguis preparation in flakes the most at last.
2. a kind of have the Chinese medicine Sanguis Draxonis extract of alpha-glucoside inhibiting activity and the prepared Sanguis Draxonis extract of preparation technology's method and the preparation thereof of preparation thereof as claimed in claim 1, its purposes is to can be used as hypoglycemic drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100282329A CN1317005C (en) | 2005-07-28 | 2005-07-28 | Dragon's blood extract with alpha-glycosidase inhibiting activity and its prepn making process and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100282329A CN1317005C (en) | 2005-07-28 | 2005-07-28 | Dragon's blood extract with alpha-glycosidase inhibiting activity and its prepn making process and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1739707A true CN1739707A (en) | 2006-03-01 |
| CN1317005C CN1317005C (en) | 2007-05-23 |
Family
ID=36092332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100282329A Expired - Fee Related CN1317005C (en) | 2005-07-28 | 2005-07-28 | Dragon's blood extract with alpha-glycosidase inhibiting activity and its prepn making process and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1317005C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101041652B (en) * | 2007-04-25 | 2010-04-21 | 上海大学 | Separating purified new bisflavone compound from dragon's blood and preparation method thereof |
| CN114053210A (en) * | 2021-10-26 | 2022-02-18 | 海南全星制药有限公司 | Mupirocin ointment and preparation method thereof |
| WO2024082330A1 (en) * | 2022-10-21 | 2024-04-25 | 湖南祥民制药有限公司 | Method for extracting resina draconis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1264550C (en) * | 2003-09-29 | 2006-07-19 | 上海大学 | Chinese medicine resina draconis extract preparing method |
-
2005
- 2005-07-28 CN CNB2005100282329A patent/CN1317005C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101041652B (en) * | 2007-04-25 | 2010-04-21 | 上海大学 | Separating purified new bisflavone compound from dragon's blood and preparation method thereof |
| CN114053210A (en) * | 2021-10-26 | 2022-02-18 | 海南全星制药有限公司 | Mupirocin ointment and preparation method thereof |
| CN114053210B (en) * | 2021-10-26 | 2023-09-29 | 海南全星制药有限公司 | Mopirocin ointment and preparation method thereof |
| WO2024082330A1 (en) * | 2022-10-21 | 2024-04-25 | 湖南祥民制药有限公司 | Method for extracting resina draconis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1317005C (en) | 2007-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1686421A (en) | Black fruit lycium plant fruit extract, its preparation method and application | |
| CN107412721B (en) | Blood sugar-reducing bitter gourd polypeptide compound capsule and preparation method thereof | |
| CN1686420A (en) | Baici plant fruit extract, its preparation method and application | |
| CN112870236B (en) | Flavone effective part of abelmoschus manihot and preparation method and application thereof | |
| CN105131142A (en) | Industrialization production method and application of acanthopanax senticosus polysaccharide | |
| CN1267113C (en) | Extract of mulberry twig and its extracting process and novel usage | |
| CN112717003A (en) | Application of tartary buckwheat flavone in preparation of medicine for treating tissue injury induced by diabetes | |
| WO2021078288A1 (en) | Activated insulin, compound momordica charantia peptide oral medicine for treatment of diabetes, and preparation method | |
| CN100509029C (en) | Preparing process of Chinese medicine dragon's blood flavone extract | |
| CN1317005C (en) | Dragon's blood extract with alpha-glycosidase inhibiting activity and its prepn making process and use | |
| CN1958617A (en) | Tea polysaccharide, preparation method, and usage | |
| CN101104013A (en) | Preparation of traditional Chinese medicine active component for treating diabetes and application thereof | |
| CN107095893B (en) | Extraction method and application of active substances of panax pseudoginseng | |
| CN1771977A (en) | Notoginseng glycol-saponin composition and its prepn and use | |
| CN105753920B (en) | A kind of method that alpha-glucosidase restrainer is extracted from litchi pulp | |
| CN1565467A (en) | Use of cornel and its extract in preparation alpha-glucosidase inhibitor medicine | |
| CN112843140B (en) | Medicine for treating thirst and conjunctival congestion caused by diabetes, preparation method and application | |
| CN107213176B (en) | Hydrangea macrophylla leaf extract, and pharmaceutical composition, preparation method and application thereof | |
| CN1456337A (en) | Balsam pear products containing multiple hypoglycemic active composition and preparation thereof | |
| CN105535947A (en) | Pharmaceutical composition for treating II-type diabetes and preparation method of pharmaceutical composition | |
| CN108704052A (en) | Hypoglycemic papaya hardship mulberry tablet or capsule and its preparation process | |
| CN101062283A (en) | Tea for reducing blood sugar and its preparing method | |
| CN101077363A (en) | Traditional Chinese medicine composition for treating angina pectoris and and preparation method and application thereof | |
| CN101181336A (en) | Method for refining valid target of bitter gourd for dropping blood sugar | |
| CN101269114A (en) | Preparation technique for lamiophlomis rotate active component extract and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070523 Termination date: 20100728 |